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Abstract
The non-muscular cells that populate the space found between cardiomyocyte fibers are known as ‘cardiac interstitial cells’
(CICs). CICs are heterogeneous in nature and include different cardiac progenitor/stem cells, cardiac fibroblasts and other
cell types. Upon heart damage CICs soon respond by initiating a reparative response that transforms with time into
extensive fibrosis and heart failure. Despite the biomedical relevance of CICs, controversy remains on the ontogenetic
relationship existing between the different cell kinds homing at the cardiac interstitium, as well as on the molecular signals
that regulate their differentiation, maturation, mutual interaction and role in adult cardiac homeostasis and disease. Our
work focuses on the analysis of epicardial-derived cells, the first cell type that colonizes the cardiac interstitium. We present
here a characterization and an experimental analysis of the differentiation potential and mobilization properties of a new
cell line derived from mouse embryonic epicardium (EPIC). Our results indicate that these cells express some markers
associated with cardiovascular stemness and retain part of the multipotent properties of embryonic epicardial derivatives,
spontaneously differentiating into smooth muscle, and fibroblast/myofibroblast-like cells. Epicardium-derived cells are also
shown to initiate a characteristic response to different growth factors, to display a characteristic proteolytic expression
profile and to degrade biological matrices in 3D in vitro assays. Taken together, these data indicate that EPICs are relevant to
the analysis of epicardial-derived CICs, and are a god model for the research on cardiac fibroblasts and the role these cells
play in ventricular remodeling in both ischemic or non/ischemic myocardial disease.
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Introduction
Cardiac muscle cells (cardiomyocytes) are frequently thought to
be the most abundant cell type in the adult heart. However,
multiple studies have shown that cardiac chamber walls comprise
high numbers of non-myocyte cells. These cells and their milieu
(the extracellular space between cardiomyocyte fibers) constitute
the cardiac interstitium [1–2]. Due to the small relative size of
cardiac interstitial cells (CICs) and the enormous contribution of
cardiomyocytes to cardiac mass, the proportion of CICs versus
cardiac muscle cells in the heart is frequently underestimated. In
this regard, recent reports suggest that CICs could represent up to
a 65% of non-cardiomyocyte cells in the organ [1–3].
The biomedical importance of CICs is illustrated by their
massive involvement in the remodeling of cardiac ventricular walls
after myocardial infarction, a phenomenon that is characterized
by a progressive fibrosis [4]. This ventricular remodeling involves
the initiation of an inflammatory response and the mobilization of
CICs. Both phenomena have been described as a normal response
of the adult heart to damage [5]. Other acquired cardiac diseases
like dilated cardiomyopathy are also characterized by fibrotic
disorders [6].
As already indicated, adult CICs are a heterogeneous popula-
tion of cells [7]. The phenotypes of CICs range from the
characteristic spindle-shaped profile of cardiac fibroblasts (CF) to
the more spherical aspect of resident cardiac progenitor/stem cells
[8]. From a molecular standpoint, CICs have been phenotyped
and classified into different categories by the expression of
fibroblastic markers like DDR-2, FSP-1, HSP47, collagen-I
[9,10]; stemness markers such as c-Kit, CD34, or Sca-1 [11–15];
or molecules classically related to cardiac embryonic progenitors
like Islet 1 (Isl1) or Gata4 [16,17].
The origin of CICs is also known to be diverse, as reported
sources for these cells include bone marrow-derived circulating
cells, perivascular cells, the endothelium/endocardium, and the
epicardium [3,7]. Interestingly, only the epicardium shows a very
early and persistent contribution to the cardiac interstitium,
starting around midgestation [7,17–19].
The embryonic epicardium is an important tissue in cardiac
development. It originates from the proepicardium, a cluster of
coelomic cells at the caudal end of the developing heart (E9.0–9.5
in the mouse). Proepicardial cells are transferred to the myocardial
surface, where they attach and spread forming a continuous
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monolayered epithelium, the epicardium [20]. While the epicar-
dial epithelium forms, an epithelial-to-mesenchymal transition
(EMT) is initiated, so that part of epicardial epithelial cells
transform into a population of mesenchymal, highly invasive,
epicardium-derived cells (EPDCs). Therefore, the proepicardial-
epicardial-EPDC transition should be considered as an anatomical
and developmental continuum.
EPDCs differentiate into coronary endothelial and smooth
muscle cells [19,21–23], and interstitial fibroblasts both in vivo and
in vitro [18,24,25]. Cardiomyocyte differentiation from epicardial
progenitors has only been fully confirmed in vitro [24,26], being the
in vivo differentiation scenario still under debate [17,27,28]. Taken
together, these results suggest that cells in the epicardial lineage
could indeed have multipotent properties [24,29,30].
Despite the biomedical importance of CICs, not many reports
have characterized these cells as related to their embryonic origin.
This approach is most relevant, as our knowledge on the biology of
the embryonic sources of CICs can provide clues to understand
the responses of the adult interstitium to stress or pathological
conditions (e.g. myocardial ischemia). Since the number of EPDCs
that can be retrieved from the embryo is really limited, the use of a
tool such as a stable cell line is necessary for detailed molecular
and experimental analyses. The main goal of this work is to
analyze CICs of epicardial origin using a continuous cell line of
epicardium-derived interstitial cells (EPIC) as a model, also
comparing its properties to those of native epicardial embryonic
derivatives.
Our work provides data suggesting that the multipotent
properties of cells in the embryonic epicardial lineage are
progressively lost throughout development, and accordingly the
EPIC line represents a post-EMT EPDC that can differentiate into
myofibroblast-like (smooth muscle-like) and fibroblastic cells, but
not into myocardial or endothelial cell types. Our results also
indicate that EPICs display a characteristic mobilization and
proteolytic program, a finding that is relevant to our knowledge of
the structure of adult cardiac interstitium, the definition of a
cardiac stem cell niche and the interstitial response to stress or
damage. This work opens new avenues for the study of cardiac
fibroblast/myofibroblast biology and the analysis of mechanisms
leading to cardiac remodeling of the diseased heart.
Materials and Methods
Ethics statement
The research on mouse embryonic tissue carried out in this
study has been approved by the Ethics Committee of the
University of Ma´laga (Spain) under a specific procedure for the
controlled breeding of mice and embryo collection. All the work
performed in this study was developed in compliance with the
Spanish (LAW 32/2007; RD142/2002; RD1201/2005) and
European regulations (Directive 86/609/EEC; Directive 2010/
63/EU; Commission Recommendation 2007/526/EC) on the use
of animals for scientific research.
Culture of embryonic proepicardial and epicardial cells
E9.5 mouse (C57BL/6) proepicardia and E11.5 embryonic
hearts were dissected in EBSS (GIBCO) using forceps, iridectomy
scissors and sharpened tungsten needles. Proepicardia were
explanted and cultured on poly-L lysinated coverslips, whereas
whole hearts were let to attach to 0.1% poly-L lysine or 0.1%
gelatin coated-coverslips. Tissues were let to attach overnight. For
whole heart explant culture, hearts were removed after an
attachment period of 24 hours, leaving characteristic halo of
epicardial cells attached to the substrate. These epicardial cells
were cultured for an extra period of 48 hours.
Generation of the EPIC cell line
The EPIC is a continuous cell line derived from E11.5 mouse
embryonic epicardium generated at the University of Ma´laga
(Spain). These cells were primarily extracted from whole E11.5
embryonic hearts as described above. Epicardial cell monolayers
were cultured for 24 extra hours in DMEM, Penicillin/Strepto-
mycin (GIBCO) and 1 mg/ml 20-methylcholanthrene (MCA,
SIGMA). Purity of primary cultures was assessed by cytokeratin
immunostaining (see below). After extensive washing with
DMEM, cells were let to grow for 4 weeks in their wells, with
new DMEM, 1% fetal bovine serum (FBS, PAA) and Penicillin/
Streptomycin added every two days. After confluence, cells were
trypsinized, replated and cultured at high concentration in
DMEM, 10% FBS and Penicillin/Streptomycin. The EPIC line
has been growing in culture for more than 3 years.
EPIC culture dynamics
For regular culture, EPIC were maintained in high glucose
DMEM supplemented with 10% FBS, 100 U/mL of penicillin,
100 mg/mL streptomycin and 25 mg/mL of plasmocin (INVIVO-
GEN), and routinely passaged at confluence.
To plot the growth curve, 104 cells were plated in 100 mm
diameter Petri dishes for 10 days; each day 3 dishes were
trypsinized and the number of cells was estimated from the
suspension in a Neubauer chamber.
Differentiation assays
To promote the differentiation of embryonic epicardial
progenitors (E9.5 proepicardial cells), E11.5 epicardial cells and
EPIC (1.66104 cells/well), samples were cultured in high glucose
DMEM supplemented with 1% FBS, 100 U/mL of penicillin and
100 mg/mL streptomycin for 24 hours. All samples were cultured
for 24 extra hours in two different media conditioned to promote
cell type-specific differentiation: 5% FBS for smooth and cardiac
striated muscle; 50 ng/mL bFGF (R&D)+100 ng/mL VEGF-A
(R&D) for vascular endothelium.
Immunohistochemical characterization
Cells were fixed in 70% methanol, Dent’s fixative (metha-
nol:DMSO, 4:1) or 4% paraformaldehyde, hydrated through a
70%, 50%, 30% ethanol series, extensively washed in PBS,
permeabilized and blocked in 5% normal goat serum, 1% bovine
serum albumin (BSA) and 0.5% Triton X-100 in Tris-PBS (SBT).
Then, cells were incubated overnight in the primary antibody
diluted in SBT [1:100 a-SMA (SIGMA); 1:20 MF20 (DSHB); 1:50
SM22 (SIGMA); 1:100 smooth muscle myosin (Biomedical
Technologies); 1:100 Pan-cytokeratin (DAKO); 1:100 Pan-Cad-
herin (SIGMA); 1:50 CD31/PECAM (BD Biosciences); 1:50
VEGFR-2 (BD Biosciences); 1:50 ZO-1 (DSHB), 1:50 Collagen I
(Calbiochem); and 1:100 FSP-1 (a kind gift from Dr. Eric G.
Neilson)]. Samples were washed in PBS and incubated again in a
secondary TRITC, Cy5 or FITC-conjugated anti-mouse IgG
(SIGMA) at 4uC (8 hours). After final washes in PBS, cell nuclei
were counterstained with DAPI (SIGMA) and samples were
analyzed under a SP5 laser confocal microscope (LEICA).
Flow cytometry
Subconfluent EPICs were trypsinized, counted and harvested
after a brief spinning. Subsequently, cells were washed once in ice
cold binding buffer (PBS with 1% BSA and 0.02% sodium azide)
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and re-suspended in the same buffer at 26106cells/ml. The cells
were then aliquoted (100 ml), incubated with 0.5 mg primary
antibodies at 4uC for 30 minutes, washed twice with binding
buffer, and finally incubated on ice and in the dark with 0.25 mg
FITC-conjugated secondary antibodies for 30 minutes. Cells were
washed twice with binding buffer and analyzed on a FACScalibur
cytometer (Becton Dickinson). Incubation with isotype IgG control
antibody was used as a negative control. All the antibodies used for
FACS were purchased from eBiosciences, except those against
VEGFR1&2, EphA1-8, EphB2-4, ephrin A1,2&4 and ephrin
B1&2 (all from R&D).
Semi-quantitative PCR characterization
Total RNA from proepicardial, E11.5 embryonic epicardial
cells and EPICs was extracted using the NucleoSpin RNA XS kit
(Macherey-Nagel) and submitted to reverse-transcription using
oligo dT18 (First Strand cDNA Synthesis Kit/AMV, ROCHE).
Ribosomal18S RNA was amplified as reference gene. Analysis of
gene expression was carried out using the QuantiTect Primer
Assays (Qiagen). The references for the specific primers are: 18s
(Mm_Rn18s_2_SG); a-SMA (Mm_Acta2_1_SG); Collagen-I
(Mm_Col1a1_1_SG); Mef2c (Mm_Mef2c_1_SG); prolyl-4 hy-
droxylase (Mm_P4hb_1_SG); SRF (Mm_Srf_1_SG); Scl/Tal1
(Mm_Tal1_1_SG); Tnnt2 (Mm_Tnnt2_1_SG); c-SMA
(Mm_Actg2_1_SG); Gata4 (Mm_Gata4_1_SG); VEGF-R2
(Mm_Kdr_1_SG); Nkx2.5 (Mm_Nkx2-5_1_SG); CD31/PECAM
(Mm_Pecam1_1_SG); Wt1 (FW.59-ATCCTCTGTGGTGCC-
CAGTA-39; RV.59-CGACAGCTGAAGGGCTTTTC-39);
Tcf21(FW.59-GGCCAACGACAAGTACGAGA -39; RV. 59-
GTTTGCCGGCCACCATAAAG-39); Sox9 (FW.59-AGGAG-
CACTGAGTCCTTTGC-39; RV. 59-CTATCCACGGCACA-
CACACT-39).
Quantitative PCR analysis
RNA was extracted from EPIC using TRIzol reagent (SIGMA)
as described by manufacturer. RNA concentration was measured
with NanoDrop, and 1 mg was submitted to reverse transcription
using oligo dT18 (First Strand cDNA Synthesis Kit/AMV,
ROCHE). 10 ng of cDNA was used for real-time PCR with
specific primers, MaximaTM SYBR Green/ROX qPCR Master
Mix (26) (Fermentas) and BioRad CFX96 Cycler. References for
primers are: MMP11 (Mm_Mmp11_1_SG), MMP14
(Mm_Mmp14_1_SG), ADAM10 (Mm_Adam10_1_SG), AD-
AM15 (Mm_Adam15_1_SG), ADAM17 (Mm_Adam17_1_SG),
ADAM19 (Mm_Adam19_1_SG), TIMP1 (Mm_TIMP1_1_SG),
TIMP2 (Mm_TIMP2_1_SG), TIMP3 (Mm_TIMP3_1_SG).
GAPDH was used as reference gene (Mm_Gapdh_3_SG).
Matrix degradation and sprouting/proteolytic assays
EPICs were cultured as previously described. Cloning of the
EPIC line was carried out by limiting dilution of the stock on 96-
well plates (CORNING). 8 different single clones were selected by
their characteristic phenotype and growth rate (cEP1–8). Cells
were re-suspended in DMEM (GIBCO) supplemented with 10%
FBS, 100 U/mL of penicillin and 100 mg/mL streptomycin and
mixed with 20% methyl cellulose (SIGMA). Then, 30 ml drops
containing an average of 750 cells per drop were distributed over
the surface of Petri dishes that were incubated (5% CO2,
overnight) for a classic hanging drop culture. Between 20–30
spheroids were used per treatment in each experiment. The
formed cell spheroids were inspected, photographed with a Leica
microscope and removed from plates by gentle washing with 5 ml
1% BSA in PBS. Cell spheroids were centrifuged for 5 min at
600 rpm and resuspended in TBS (20 mM Tris pH7.5; 150 mM
NaCl). To proceed with the sprouting/proteolytic assay, 500 ml of
regular 3D fibrin gels (5 mg/ml) were formed on the bottom of
24well cell culture plates by the addition of 0.2 U/ml thrombin
[31]. Then, a second fibrin gel layer including transglutaminase
bound (TG-bound) growth factors [TG-BMP2 (1 mg/ml) and TG-
VEGF121 (100 ng/ml)] or soluble factors [bFGF, Wnt3a and
Wnt5a (100 ng/ml)] was used to seed EPIC spheroids on top of
the first gel layer. TG-binding of growth factors to the fibrin gel
allows for the covalent attachment of these molecules to the
matrix. Spheroids were photographed after 3 h, 12, 24, 48 and
72 hours time intervals. The digested and/or sprouting area was
calculated using Olympus software and plotted as square
micrometers. Quantification of differences in sprouting and
proteolysis was performed for each individual clone by compiling
the spheroid occupied area/digested area when projected into a 2-
D image.
For zymography assays, cEP4, EPIC and HT1080 cells were
cultured in 100 ml fibrinogen gels (0.36106cells/gel) supplemented
with 200 ml DMEM (without serum). After 24 hours the medium
from each culture was collected, centrifuged to remove cell debris
and mixed with 46 loading buffer (0.4 M TrisHCl, pH 6.8; 20%
glycerol; 0.03% bromophenolblue). 20 mL samples were loaded in
each lane and MMP activity was analyzed using gelatine
zymography (48 hours). Briefly, 1.5 mg/ml final concentration
of gelatin (AppliChem) was added to a 10% standard Laemmli
acrylamide polymerization mixture. Human plasmin (FLUCKA)
or supernatant from HT1080 cells were loaded as controls. After
electrophoresis, gels were incubated twice in 2.5% Triton X-100
(30 min) and then in the zymograpy buffer (50 mMTrisHCl
pH 7.5; 200 mM NaCl; 5 mM CaCl2; 0.02% NaN3; 37uC). Gels
were stained with Colloidal blue staining solution (Invitrogen)
following the instructions of the provider. Proteolytic activity was
visualized as white bands against a blue background. An
alternative, independent experiment to test the proteolytic activity
of cEP4 was performed culturing these cells in 3D fibrin gels
(DMEM/12+1% ITS, no serum) and treating experimental
groups with the protease inhibitor aprotinin (1 mg/ml).
Results
Generation and characterization of the EPIC line
After 48 hours of culture, E11.5 epicardial embryonic cells grew
over the substrate and formed a characteristic halo around the
explant (Fig. 1A–C). This halo of epicardial cells expressed high
levels of cytokeratin (Fig. 1D–E). After incubation with methyl-
cholanthrene (MCA) and sustained culture for one month intense
proliferation of primary epicardial cells was recorded. Between the
first and third passages the majority of these cells had acquired a
mesenchymal phenotype, Continuous passage of cells led to the
stabilization of the EPIC line, which have been continuously
growing in culture for more than three years.
EPICs were found to have a morphologically heterogeneous
appearance; the majority of the cells displayed a mesenchymal
phenotype (Fig. 1F,F9) a result that was partially supported by
sqPCR analysis of epicardial mesenchymal markers (Sox9 and
Tcf21, Fig. 1G). However, a minor number of EPICs grew closely
associated when cultured at low densities thus resembling
epithelial cells (Fig. 1H). The epithelial-like nature of these small
clones was confirmed by immunohistochemistry using ZO-1 and
anti-Pan-cadherin antibodies (Fig. 1I,J). In parallel, we evaluated
the growth capacity of EPICs and plotted it into a growth curve
(Fig. 1K). Our study indicates that EPICs have a short lag state
(20 h), suggesting a good adaptation to in vitro culture growth, a log
phase with a reduced initial growth rate followed by a faster one
Epicardial-Derived Interstitial Cells
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(see Fig. 1K), and a stationary phase characterized by a slow but
continuous cell division, indicating that EPIC do not present
contact-dependent inhibition of growth.
EPIC differentiation potential
As already indicated, epicardial embryonic progenitors (the
transient proepicardial cells) are known to display multipotent
properties both in vivo and in vitro, although it is not well known
whether this multipotency is totally or partially retained by their
derivatives [24,25]. We have therefore compared EPIC differen-
tiation potential to that of embryonic proepicardial (E9.5) and
epicardial (E11.5) primary explants, focusing on the four principal
cell fates described for embryonic EPDCs (endothelium, smooth
muscle, cardiomyocytes and fibroblasts) [18,19,24,31]. Using
different growth factor-supplemented media (see Material &
Methods) followed by immunohistochemical characterization,
cultured proepicardial cells were shown to differentiate into cells
expressing myocardial (sarcomeric myosin), endothelial (CD31),
smooth muscle/myofibroblast-like (a-SMA) and fibroblastic (FSP-
1) cell markers (Fig. 2A,B,E,F,I,J,M,N). E11.5 epicardial explants
did not express proteins of differentiated cardiomyocytes
(Fig. 2C,D), nor endothelial antigens (Fig. 2G,H) in our explant
system; the majority of CD31+ subepicardial coronary vascular
progenitors cells and endothelial cords did not migrate from the
whole heart explants onto the cell culture substrate (Fig. S1A,B).
However, the expression of a-SMA (Fig. 2K,L) and the fibroblastic
antigen FSP-1 (Fig. 2O,P) was conspicuous in these E11.5
embryonic epicardial cells.
EPICs consistently expressed specific markers for myofibroblasts
(a-SMA, 68.2%), smooth muscle cell (SM22, 21.9%) (Fig. 3A,F,
Fig. S1E, Fig. S2), and fibroblasts (FSP-1, 18.5%; Collagen I,
42.2%) (Fig. 3G–I), but are negative for endothelial cell (Fig. S1D;
compare to the control VEGFR-2 staining in Fig. S1C) or
cardiomyocyte markers (not shown). Treatment of EPICs with
TGFb1,2 did not significantly alter the number of a-SMA+ or
SM22+ cells (Fig. 3D–F), but had an impact on gene expression
levels (a-SMA and c-SMA for TGFb1 and only c-SMA for
TGFb2, Fig. S2) and morphology of the cells, which spread over
the culture displaying long, apparent filopodia and lamellipodia
(Fig. 3D–F). Further characterization of EPICs by sqPCR
confirmed the expression of smooth muscle (a-SMA, c-SMA)
and fibroblastic markers (collagen I; prolyl-hydroxylase 4) in these
cells (Fig. 3J). Although EPICs did not seem to differentiate into
cardiac striated muscle or endothelial cells, they maintained the
expression of some pre-cardiogenic (Gata4, Nkx2.5 and SRF, but
not Mef2c, Fig. 3J) and endothelial-related transcription factors
(SCL/Tal1, Fig.?3J). EPICs also expressed Wilms tumor suppres-
sor gene transcription factor (Wt1) (Fig. 3J), characteristic of
embryonic epicardium [29]. In accordance with the immunohis-
tochemical data presented above (Fig. 2), proepicardial cells (E9.5)
and embryonic epicardial (E11.5) cells expressed a diversity of
markers for endothelial, smooth muscle, cardiac muscle and
fibroblastic cells (Fig. 3J).
Cell surface marker profiling
In order to characterize the EPIC line, we analyzed the
expression of cell surface antigens by FACS (Fig. 4). While EPIC
were positive for the stemness-like/progenitor markers Sca1,
CD44, CD140a (PDGFRa; low expression), CD140b (PDGFRb),
they were negative for CD117 (c-Kit), and CD90 (Thy1). Although
markers related to cardiovascular embryonic development like Flt-
1 (VEGFR-1) and CD106 (VCAM) have been identified in EPIC,
other markers which are continuously present on cells of the
endothelial lineage (CD31/PECAM-1, Flk-1/VEGFR-2, Notch1)
were absent. Finally, various ephrin ligands and Eph receptors
have been found to be expressed by EPIC. In detail, EPICs were
positive for ephrin receptors (Eph) EphB3, B4, A2, A4, but
negative for EphA1, EphA3, EphA5, EphA6, EphA7, EphA8 and
EphB2. Regarding the ligands, EphrinB1 and B2, but not ephrins
A1, A2, A4, were present in EPIC. (Fig. S3).
Proteolytic activity and sprouting capacity of EPIC
Embryonic EPDCs and cardiac fibroblasts are known to be able
to migrate through and degrade the extracellular matrix (ECM).
To test the proteolytic activity of the EPIC line we established a
3D culture assay in which EPIC spheroids generated by a classic
hanging drop method (with EPICs suspended in methylcellulose
containing medium) were cultured in growth factor-loaded fibrin
gels microenvironments. Spherical aggregates of EPICs cultured in
control fibrin gels actively degraded this matrix as illustrated by
the formation of a proteolysis halo around the cells (Fig. 5A).
When the spheroids were treated with soluble bFGF, Wnt3a and
Wnt5a, EPICs showed a reduced proteolytic activity (as identified
by the reduction of the proteolysis halo) (Fig. 5A). In an additional
series of experiments, EPICs were grown within fibrin gels
containing engineered growth factors (TG-BMP2 and TG-
VEGF121), which are covalently tethered to the fibrin network
by the human transglutaminase (TG) factor XIII [31], and gels
without growth factors (Fig. 5A). TG-BMP2 and TG-VEGF121
decorated fibrin gels promoted the attachment, migration and
spreading of EPICs without massive degradation of the gel
(‘sprouting’ phenotype, see also Fig. 6B). Routine tests were
performed to check whether EPICs differentiation into endothe-
lium (VEGF treatment) [22] or cardiac muscle (BMP-2 treatment)
[24] was occurring in fibrin gels with TG-bound growth factors.
No differentiation into these cell types could be recorded (VE-
cadherin, VEGFR2, myocardin, Mef2c sqPCRs, data not shown).
qPCR analysis of EPICs, as compared with E11.5 whole hearts,
demonstrated a characteristic expression profile for a variety of
molecules involved in the regulation of ECM proteolytic
degradation, mostly MMPs, ADAMs, and TIMPs (Fig. 5B). The
EPIC line preferentially expresses MMP-11, ADAM, 15 and
TIMP-1, 2 and 3, displaying a decreased expression of ADAM 17
and 19 as compared to embryonic heart tissue. No differences
were found for MMP-14 and ADAM-10 (Fig. 5B).
Proteolytic activity and sprouting capacity of EPIC clones
Since different cellular cell phenotypes were identified in the
EPIC line, various EPIC clones were isolated by critical dilution
Figure 1. EPIC generation and characterization. A–C. Primary culture of E11.5 embryonic epicardium. A. Whole heart culture. B. Detail showing
the outgrowth of epicardial cells from the explanted hearts. C. Epicardial cell halo growing on gelatin-coated coverslips. D,E. Epicardial cells normally
express cytokeratin, a marker for epicardial cells. F-F9. The majority of EPICs display a mesenchymal phenotype (F, confluent culture; F9, subconfluent
culture) and express Sox9, a known marker for epicardial mesenchymal cells. However, EPICs do not express Tcf21 (G). A few, small epithelial-like cell
clones (H, dotted line) are found dispersed in the culture. Cells in these clones express the epithelial markers ZO-1 (I) and cadherins (J). K. EPIC
growth dynamics. The graph shows the parameters defining EPIC cell growth in culture (lag time; population doubling time; plateau level; and
saturation density). Scale bars: A,C,D = 100 mm; B,E,F,G = 50 mm; H = ; I,J = 20 mm.
doi:10.1371/journal.pone.0053694.g001
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and 8 of them (cEP1–8) were selected for experimentation as based
on their morphology and proliferative activity (Fig. 6A).
Cell spheroids from EPIC clones cultured in 3D fibrin matrices
showed different behaviors (Fig. 6B, left). Some clones exhibited
extraordinary proteolytic capacity, identified by the appearance of
a matrix degradation halo around the cell spheroids. Proteolysis
was visible as early as 2–3 h after embedding spheroids in 3D
matrices, and the complete degradation of the embedding fibrin
was effective within 2 to 5 days (measured by the contact of the cell
spheroids to the plastic). Fibrin degradation was found to be fast in
cEP4,5,8, slower in cEP1-3 and very slow in cEP6,7 (Fig. 6B,
middle). Remarkably, cEP6,7 displayed a characteristic ‘sprouting’
response after 48 hours that was absent in clones cEP4,5 and cEP8
(data not shown). Cell proteolytic activity was evaluated by
estimating the digested area around spheroids, and the different
cell clones were plotted for proteolysis (Y axis) and sprouting (X
axis) (Fig. 6B, right). We observed an inverse relation between
sprouting and the ability to digest the fibrin matrix (Fig. 6B and
Fig. S4). Cells with the highest proteolytic activity group together
(clones cEP1–cEP5) in the same cluster, while cells with clear
sprouting activity group in a different cluster (Clones cEP6 and
cEP7) (Fig. 6B, right). In order to determine whether the
differences observed in 3D matrix degradation of EPIC clones
correlate with certain proteases, we performed MMP, ADAM and
TIMP mRNA profile analyses by qPCR (Fig. 6C). For these
analyses clones representing the most extreme proteolytic activity
(cEP4), the highest sprouting activity (cEP7) and intermediate
properties (cEP6) were selected. Three independent qPCR
experiments were run, with GAPDH as a reference gene. The
results from these analyses indicated significant changes in the
expression of MMP-11 and 14; ADAM-10, 15, 17 and 19; TIMP-
1, 2, and 3 between different clones (Fig. 6C). To confirm the
proteolytic properties of EPICs, cEP4 cells were cultured on fibrin
gels containing the protease inhibitor aprotinin. Proteolysis in
these gels was significantly reduced in these cultures as compared
to control (no aprotinin) ones. The supernatant from EPICS and
cEP4 cultures was also used for zymography assays. The results
independently confirmed the proteolytic properties of EPICs (Fig.
S5).
In parallel, cEP1–8 cell spheroids were embedded in a two-layer
engineered fibrin matrix with transglutaminase(TG)-bound-BMP-
2 or -VEGF (Fig. S4A). Exposure to these engineered 3D fibrin
gels did not result in any observable changes in the differentiation
of these cells towards endothelial or cardiomyocyte lineages (data
not shown). However, some clones, when exposed to matrix-
bound TG-BMP-2 (cEP6, cEP7) or TG-VEGF121 (cEP7),
displayed variable degrees of cell sprouting into the fibrin gel
with fast outward cell migration (Fig. S4A). All the other clones did
not show any sprouting response under these experimental
conditions, but instead degraded the surrounding matrix after
Figure 2. Differentiation potential along the proepicardium-epicardium transition. Proepicardia cultured in vitro express differentiation
markers for striated heart muscle (MF20, A, B), endothelial progenitors/cells (E, F), smooth muscle cells (I, J) and fibroblasts (M, N). E11.5 epicardial
cells do not express myocardial (C, D) or endothelial markers (G, H), but continue to express smooth muscle (a-SMA, K, L) and fibroblastic ones (FSP-
1, O, P). Scale bars: A,C,E,G,I,K,M = 100 mm; B,D,F,H,J,L,N,O = 50 mm; P = 25 mm.
doi:10.1371/journal.pone.0053694.g002
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48 hours in culture. Since most cell spheroids did not show a
response to VEGF, we used as control HUVEC cells to
demonstrate that TG-VEGF121 incorporated into fibrin gels is
fully functional. Indeed, HUVEC cells seeded in matrix with TG-
VEGF121 readily migrated from the original spheroids. To
evaluate TG-BMP-2 signalling activity, both BMPRI expression
and pSMAD phosphorylation were confirmed (not shown) (Fig.
S4A). Finally, the most extreme ‘sprouting’ phenotype (cEP7) was
chosen for a detailed profiling. cEP7 cells migrate in response to
TG-BMP2 and TG-VEGF121, as well as to bFGF embedded
within fibrin (Fig. S4B). Wnt3a and Wnt5a treatments reduced the
proteolytic activity of EPIC as compared to control cultures. The
sprouting area for cEP7 in response to different growth factors was
plotted as fold differences with respect to untreated control sets
(Fig. S4B).
Discussion
In this study we have analyzed the phenotype and properties of
the epicardium-derived component of cardiac interstitial cells
(CICs). We have focused our research on this CIC subpopulation
for three different reasons. First, because embryonic epicardial
mesenchymal derivatives (EPDCs) pioneer the colonization of the
cardiac interstitial space, remaining as part of the cardiac
interstitium throughout adulthood [17,18,26,32–34]. Since the
cardiac interstitium becomes more complex with time, interstitial
cells of epicardial origin are likely to be involved in the progressive
recruitment of cells from different origins to the cardiac
interstitium. Second, EPDCs are known to invade multiple
cardiac tissues, differentiating into a variety of cell kinds
[18,19,35,36]. This phenomenon requires the active migration
of EPDCs, and thus the activation of efficient mobilization and
proteolytic programs. Third, some EPDCs have been shown to
differentiate into CFs [18], a cell type responsible for the fibrotic
ventricular remodeling that follows chronic cardiac infarction.
Due to the complex biology of CICs (including CFs), new in vitro
models to study the diversity and behavior of these cells under
normal and pathologic conditions are needed. Other works have
reported the use of epicardial continuous cell lines derived from
neonatal rat epicardium [37,38] or mouse embryonic epicardium
[39,40]. However, in most cases, these cell lines retain a full
epithelial phenotype and are a poor model for epicardial
mesenchymal derivatives, which display unique migratory and
proteolytic properties.
Our work uses a new immortalized embryonic epicardial cell
line derived from ED11.5 mouse hearts (EPIC). Original
embryonic epicardial epithelial cells explanted in vitro continuously
proliferate and expand, acquiring a characteristic mesenchymal
phenotype and expressing known mesenchymal markers like Sox9.
We have however identified in our cell line a few, small clones of
cells that display an epithelial-like phenotype (Pan-Cadherin+,
ZO-1+) (Fig. 1). The appearance of such cells can be the result of
the immortalization procedure, but also illustrate a dynamic
phenotypical plasticity between embryonic epicardial epithelial
cells and their mesenchymal derivatives.
Since embryonic (pro)epicardial cells have been reported to
differentiate into various cell types [18,19,24], and thus suggested
to be multipotent [29], we have evaluated the differentiation
potential of the EPIC line. In order to do so, we have first
compared EPICs with epicardial progenitor cells (proepicardium)
and E11.5 embryonic epicardial cells to screen the differentiation
potential of the cells along the proepicardial-epicardial-EPDC
developmental continuum. Mouse epicardial progenitor cells
Figure 3. EPIC differentiation marker expression. A–C. EPIC express a-SMA (red) and SM22 (green). D–F Treatment with TGFb1,2 does not
altere the number of cells expressing these two markers, but affects the phenotype of the cells which spread and elongate in culture. EPICs also
express fibroblast protein markers like FSP-1 (G,H) and Collagen I (I; I9 shows the negative, non-inmune control for collagen I immunohistochemistry).
J. sqPCR profiling. EPIC (left column), E9.5 proepicardium (middle columns) and E11.5 epicardium (right column). Scale bars: A,B,C,D,E,F,H,I9= 65 mm;
G = 100 mm; I = 10 mm.
doi:10.1371/journal.pone.0053694.g003
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(proepicardial cells) are shown to differentiate into endothelial and
smooth muscle cells, cardiomyocytes and fibroblasts. In contrast,
cultured E11.5 epicardial cells and EPICs only express markers for
smooth muscle cells (a-SMA) and fibroblasts (FSP1), and seem to
have lost their potential to spontaneously differentiate into
endothelial cells (CD31) or cardiomyocytes (MF20) in vitro. These
data could be interpreted as the result of a progressive restriction
of the developmental multipotency of epicardial progenitor cells as
they transform into epicardial cells and EPDCs. However, it is not
clear whether the full differentiation potential of epicardial cells is
truly lost or the experimental procedure we have used fails to
promote the outgrowth and propagation of specific progenitor cell
types from the explants, as we have shown is the case of CD31+
coronary epicardial progenitors. In this context it is important to
emphasize that our mRNA expression studies show that some
markers for endothelial cells (Scl/Tal1) and cardiac muscle
progenitors (Nkx2.5; Gata4; Srf) are expressed by EPICs even if
they do not terminally differentiate into these cell types. This
suggests that the endothelial/cardiomyocyte differentiation poten-
tial of embryonic EPDCs is not fully abrogated in the EPIC line, a
concept supported by its basal expression of Wt1, a marker for
non-differentiated embryonic EPDCs [41]. It is thus tempting to
speculate that epicardial mesenchymal derivatives could differen-
tiate into endothelial cells or cardiomyocytes if instructed with the
proper signals. The latter interpretation is in accordance with
recently published results suggesting that thymosin b4-dependent
reprogramming of adult epicardial cells (from a Wt1+ lineage)
allows these cells to recapitulate their embryonic potential and to
differentiate into endothelium, smooth muscle and cardiomyocytes
[42,43].
Our results indicate that EPICs robustly differentiate into
myofibroblast-like cells (a-SMA), smooth muscle cells (a-SMA/c-
SMA/SM-22+) and fibroblasts (FSP-1, collagen I, prolyl-hydrox-
ylase 4). Interestingly enough, the percentage of a-SMA/SM-22+
cells is low if compared with the extensive expression of a-SMA/
SM-22+ in a high percentage of EPICs, and it is therefore possible
that a-SMA+ cells both represent myofibroblasts and immature
smooth muscle cells. In this respect, recent reports have indicated
that the differential expression of PDGFRa and b [33,34,41] is
pivotal to the segregation of fibroblastic and smooth muscle cell
lineages, respectively, from a common pool of EPDC progenitor
cells [34]. In this study we show that EPICs express both PDGFRa
and b and could be a good model to study smooth muscle versus
cardiac fibroblast differentiation. Moreover, we would like to
propose that the ‘myofibroblastic’ phenotype of some activated
CF, including the massive expression of a-SMA, could be related
to the epicardial origin of such cells, which might share a common
progenitor with some cardiac smooth muscle cells. In this scenario,
Figure 4. EPIC cell surface marker expression (FACS). EPIC expression of cell surface markers was evaluated by flow cytometry. Additional
FACS analyses on ephrin and Eph receptors can be found in Fig. S4.
doi:10.1371/journal.pone.0053694.g004
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the genetic and signaling embryonic programs regulating epicar-
dial cell differentiation, like those dependent on differential
signaling via PDGF receptors alpha and beta, could also be
responsible for the modulation of CF phenotype in the adult life.
Such phenotype is dynamic, as shown by the variable expression of
fibroblasts markers like FSP-1 (expressed in a small proportion of
EPICs) or collagen I (expressed by a higher number of EPICs).
In relation to the migratory properties of the EPIC line, we have
described the expression of molecules involved in the active
migration of EPDCs like ephrins and their Eph receptors [44]
through FACS analysis (Fig. S3). Remarkably, EphA2+ human
cardiac stem cells have been described to be dependent on this
ephrin receptor to migrate in response to myocardial infarction
[45], but it is not known if the stem cells described in this work
derive from the epicardium, as suggested for other cardiac stem
cells [35]. On the other hand, the segregated expression of ephrins
and Eph receptors in epicardial derivatives and other cell types in
the cardiac interstitium could be instrumental to build up a
functional cardiac niche microenvironment for cardiovascular
progenitor/stem cells.
EPICs also express a variety of cell surface markers related to
EPDC/fibroblastic adhesion to the ECM [46] and cell mobiliza-
tion/migration [47] like CD106/VCAM [34]. Additional analyses
of standard markers for stem-like/progenitor cells indicate that
EPICs are Sca1-positive but c-kit- and CD90-negative, an
expression profile previously described for some CSC [48]. EPIC
also express other markers associated with mesenchymal stem cells
like CD44 [49]. These results are in agreement with a recent
report supporting the epicardial origin of a population of cardiac
stem cells [35].
As it can be inferred from the previous paragraph, migration of
CICs necessarily involves active ECM proteolysis, but also an
efficient attachment of cells to the matrix. Our experimental
setting compares the response of EPICs to regular and engineered
fibrin gels (with TG-bound growth factors). Covalent binding of
growth factors like BMP2 and VEGF to fibrin enhances cell
attachment and spreading (‘sprouting’) of EPICs to the matrix
without its massive degradation, whereas culturing these same cells
on regular fibrin gels rather activates a strong proteolytic response.
Then, the addition of soluble, non fibrin-bound Wnt3a and 5a
abrogates EPIC degradation of fibrin matrices in our experiments,
suggesting a limited migratory ability for these cells. As a matter of
fact, it has been reported that Wnts can inhibit the migration of rat
cardiac fibroblasts [50]. All these data, taken together, indicate
that a fine balance between different signals is necessary to
promote an efficient and permissive degradation of the matrix so
that cells can initiate migration.
Matrix metalloproteinases (MMPs), endogenous tissue inhibitors
of metalloproteinases (TIMPs), and disintigrin and metalloprotei-
nase (ADAM) family proteins are known to be the main agents of
ECM remodeling [5]. Our EPIC line displays a high expression
level of MMP-11, ADAM-15 and TIMP-1, 2 and 3 as compared
with E11.5 whole heart tissue. EPICs also express MM-14 and
ADAM-10, but at a similar level to that found in embryonic whole
heart extracts. This proteolytic profile correlates with an effective
degradation of fibrin gels in vitro. Deficiencies in TIMP-2 activity
after myocardial infarction accelerates adverse myocardial remod-
eling due to enhanced MMP-14 activity [51]. These results may
suggest that the response of different CICs to heart damage,
specially that of CFs, is diverse, and may be linked to endogenous
proteolytic programs that, in turn, could relate to the embryonic
origin of CFs. In this regard, TIMP-2 and MMP-14 are known to
be involved in the activation of pro-MMP-2 via the formation of a
trimolecular complex at the cell surface [51], which might play
multiple roles in ECM remodeling processes, including the
promotion of 3D gels invasion by human mesenchymal stem cells
Figure 5. MMPs, ADAMs & TIMPs expression. A. EPIC spheroids cultured on regular fibrin gels (treated or un-treated with soluble bFGF, Wnt3a
or Wnt5a) or on transglutaminase-bound BMP2 or VEGF fibrin gels for 48 hours. Matrix degradation is indicated by an halo around the cell spheroids.
B. qPCR study of MMP, ADAM and TIMP expression levels. (p,0.05). Scale bars: 100 mm.
doi:10.1371/journal.pone.0053694.g005
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[52] and various CD44+ cell lines [53]. It is thus reasonable to
suggest that the whole proteolytic program active during
pathologic ventricular remodeling could depend on the interaction
of CF subpopulations of various origins with very different
proteolytic potentials.
Since the heterogeneous morphology and molecular phenotype
of EPICs suggests that different EPIC subpopulations could have
different migratory properties, we decided to analyze the
proteolytic profile of various EPIC clones. Functional fibrin
matrix degradation assays indicate that some clones present a fast
fibrin degradation rate (cEP4, 5, 8), whereas other clones degrade
the matrix in a slow manner but have a patent sprouting activity
(cEP6, 7). We have found that EPIC fibrin degradation and
sprouting over the matrix are negatively correlated. We interpret
that EPIC clones with a high proteolytic activity degrade the
matrix so fast that they fail to progress in cell-to-matrix adhesion
and subsequent migration (represented by the ‘sprouting’ pheno-
type). This hypothesis would support the concept of CF activation
and involvement in ventricular remodeling as a result of the
interaction of different CF subpopulations. The analysis of our
results indicates that the EPIC clone showing the highest sprouting
activity (cEP7) mainly expresses high levels of MMP-14, ADAM-
17 and TIMP-1 and 3, whereas the clone with extreme proteolytic
properties (cEP4) mostly activates ADAM-10, sustaining a most
balanced expression of other molecules like ADAM-15 or 19 or
TIMPs. Hence, the role of the whole cardiac interstitium as an
interactive community of cells (some of them sustaining de novo
myocardial differentiation or myocardial survival, others develop-
ing a stromal, feeder-like role) could be instrumental to define their
functions in reparative responses of the damaged heart [54]. Still,
more research is required to identify the subpopulations of CICs
(of epicardial and non-epicardial origin) that drive massive fibrotic
responses in the diseased heart.
In conclusion, this study indicates that EPICs retain the ability
to differentiate into various cardiovascular cell kinds, especially
those related to cardiac interstitium development (myofibroblasts
and CFs). Furthermore, EPIC display a complex proteolytic
program built from the interaction of the characteristic proteolytic
properties of EPIC subpopulations. Finally, EPICs could be used
as a good model to study ventricular remodeling by contributing to
Figure 6. Evaluation of EPIC clones (cEP) proteolytic activity and sprouting. A. Representative images are shown for the culture of EPIC
clones (cEP1–8) in 3D fibrin gels. B. The phenotype of the clones is illustrated in the left table. Note that some cell spheroids (asterisks) preferentially
degrade the fibrin (‘proteolytic’ clones), generating characteristic halo around the cells (arrowheads). Others (‘sprouting’ clones) attach to the fibrin
and spread over it forming multicellular sprouts (arrowheads). The fibrin gel digested area was graphically represented for each clone (middle) and
plotted against the respective sprouting area of each clone (mm2, right). C. qPCR analyses of MMP, ADAM and TIMP expression in three significant cEP
(cEP4 for maximal proteolysis and cEP6,7 for maximal sprouting). (p,0.05). Scale bars: 100 mm.
doi:10.1371/journal.pone.0053694.g006
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the identification of signaling pathways related to cardiac
interstitium homeostasis and cell surface molecular profiles that
could be used to characterize and isolate subpopulations of
epicardial-derived CFs. This, in turn, could be instrumental to
identify the roles that different CICs play in response to heart
damage (i.e. fibrosis or active ECM degradation). A great variety
of essential questions related to the maturation and response of
CICs to episodes of hypoxia or inflammation remain open, and
extensive and systematic research is required to develop new
strategies to minimize cardiac fibrotic disease.
Supporting Information
Figure S1 Coronary endothelial angioblasts/cells do not follow
epicardial outgrowth in vitro. A. CD31 whole mount immunohis-
tochemistry labels early subepicardial coronary angioblasts and
endothelial cells (arrowheads). This kind of cell is absent from
epicardial cell outgrowths in E11.5 whole heart explants (please,
refer to Fig. 2G,H). B-B9. Microdissection of E11.5 mouse hearts
in cold trypsin allows for the manual isolation of embryonic
epicardial cells. Note that after this mechanical extraction, CD31+
angioblasts/endothelial cells can be found in epicardial explants in
vitro (green). C–D. VEGFR-2 immunohistochemistry identifies
vascular endothelium (asterisk, green) and angioblasts (arrow-
heads, green) in E13.5 mouse embryo samples (C), while EPICs
remain VEGFR-2-negative (D). E. EPICs are immunoreactive to
smooth muscle-specific myosin antibodies (red cells, arrowheads).
Scale bars: A,B,C = 100 mm; B9,D,E = 50 mm.
(EPS)
Figure S2 Quantification of a and cSMA expression in TGFb-
induced EPIC cultures. Quantitative PCR confirms the increased
expression of a- and c-SMA in TGFb1-treated EPICs (left).
TGFb2-treated cultures show an increased expression of c-SMA
but not a-SMA (p value,0.05).
(EPS)
Figure S3 Ephrin and Eph EPIC profiling. Expression of Ephrin
ligand and ephrin receptor (Eph) in EPICs.
(EPS)
Figure S4 cEP behaviour on TG-fibrin matrices: proteolytic
activity and sprouting. A. cEP spheroids show different proteolyt-
ic/sprouting responses when cultured in TG-BPM2 and TG-
VEGF fibrin matrices as compared to control experiments (regular
fibrin). HUVEC cells are shown as internal control for VEGF
activity. B. cEP7 spheroids were embedded into a 3D fibrin matrix
with TG-bound-BMP2 and -VEGF121 or soluble bFGF, Wnt3a,
Wnt5a, and examined after 48 h. cEP sprouting quantification
after the different treatments has been graphically presented. Scale
bars: 100 mm.
(EPS)
Figure S5 cEP4 zymography and protease inhibitor assays. A.
10% SDS-PAGE gels with 1.5 mg/ml gelatin were used to run cell
culture supernatants. Gelatin degradation (48 hours of zymo-
graphic reaction) is shown for media from cEP4, EPICs, and
proper controls, including plain culture medium, plasmin and
supernatant from HT1080 cells (HT1080 is a fibrosarcoma line
known to express MMPs after TPA phorbol ester treatment). B.
After 24 h cEP4 cells cultured on fibrin gels degrade the substrate
and aggregate at the bottom of the culture dish (left, asterisk).
Treatment with aprotinin reduces proteolysis and cells remain in
the surface of the fibrin gel (arrowheads).
(EPS)
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